Ariad Pharmaceuticals — J.P. Morgan Healthcare Conference 2015
26 slides from Ariad Pharmaceuticals's conference presentation, Jan 14, 2015

Slide 1: Path to Value and Profitability
Path to Value and Profitability Elsa So Non-small cell lung cancer ARIAD clinical trial patient Harvey J. Berger M.D. Chairman and Chief Executive Officer ARIAD Pharmaceuticals, Inc.

Slide 2: Forward-looking statements
01.14.2015 J.P. Morgan Healthcare Conference Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors, risks and uncertainties (such as those detailed in the Company’s period

Slide 3: ARIAD 2014: key areas of progress
01.14.2015 J.P. Morgan Healthcare Conference ARIAD 2014: key areas of progress Re-launched Iclusig in the U.S. with ~800 patients treated Successfully completed EMA review - Iclusig indication statement unchanged Improved understanding of benefit/risk profile of ponatinib Achieved positive P&R outco

Slide 4: ARIAD 2015: our strategic focus
01.14.2015 J.P. Morgan Healthcare Conference 4 ARIAD 2015: our strategic focus Expand the Iclusig global commercial opportunity Leverage existing commercial infrastructure and investment Secure a broad partnership for brigatinib Invest in randomized trials to advance Iclusig and brigatinib into earl

Slide 5: Iclusig: seeking to expand the global opportunity in resistant Ph+ leukemias
01.14.2015 J.P. Morgan Healthcare Conference 5 Iclusig: seeking to expand the global opportunity in resistant Ph+ leukemias Early-switch 2nd line 2nd line 3rd line No other options T315I

Slide 6: Iclusig: seeking to expand the global opportunity in resistant Ph+ leukemias
01.14.2015 J.P. Morgan Healthcare Conference Iclusig: seeking to expand the global opportunity in resistant Ph+ leukemias Chronic Phase Accelerated Phase Blast Phase Ph+ ALL

Slide 7: Iclusig: leverage existing infrastructure and investment
01.14.2015 J.P. Morgan Healthcare Conference Iclusig: leverage existing infrastructure and investment U.S. and Europe Further expand into chronic-phase disease and earlier lines of therapy Advance to market leader in 3rd line chronic-phase CML Continue launching throughout EU28 countries* Japan Otsu

Slide 8: ARIAD and Otsuka: a strategic Iclusig partnership in Japan and Asia
01.14.2015 J.P. Morgan Healthcare Conference ARIAD and Otsuka: a strategic Iclusig partnership in Japan and Asia Existing hematology sales force with CML TKI experience Exclusive commercialization by Otsuka in ten Asian countries Building major hematology/oncology business in Territory $77.5 million

Slide 9: 2018: product revenues reach >$400M
01.14.2015 J.P. Morgan Healthcare Conference 2018: product revenues reach >$400M Revenue projections do not assume an Iclusig 2nd line indication in the U.S. or an expanded 2nd line indication in Europe during this timeframe. Global product revenue – with no change to U.S./EU Iclusig label $0 $100 $

Slide 10: Iclusig: potential 2nd line indication more than doubles the opportunity
01.14.2015 J.P. Morgan Healthcare Conference Iclusig: potential 2nd line indication more than doubles the Iclusig opportunity Potential annual CML patients eligible for Iclusig in 2018/2019 ~3,300 U.S. Source: Kantar Health and internal data; ROW= Rest of world Europe ~4,000 Japan ~800 ROW ~1,000

Slide 11: Lung Cancer: two distinct opportunities
01.14.2015 J.P. Morgan Healthcare Conference Brigatinib – ALK+ NSCLC AP32788 – NSCLC Lung Cancer: two distinct opportunities - Potential best-in-class orally active TKI - Highly competitive profile expected to garner significant market share - Global market approaches $2B by 2020 - Orally active TKI

Slide 12: Brigatinib: maximizing the full value
01.14.2015 J.P. Morgan Healthcare Conference Brigatinib: maximizing the full value Secure a broad partnership to co-develop and co-commercialize brigatinib in 2015 - Leverage existing infrastructure and capabilities - Accelerate randomized, 1st line trial against crizotinib - Explore new combination

Slide 13: ALK+ NSCLC market: a significant opportunity
01.14.2015 J.P. Morgan Healthcare Conference ALK + NSCLC market: a significant opportunity 2015 annual incidence ~9,000 U.S. Europe ~5,500 Japan ~3,500 ROW ~4,700 Sources: SEER Cancer Statistics Review 1975-2010; UpToDate; 2012 SEER Data (Cancer Statistics Review, 1975-2008); Cancer.gov; incidence r

Slide 14: ALK+ NSCLC market: approaching $2B in years
01.14.2015 J.P. Morgan Healthcare Conference ALK+ NSCLC market: approaching $2B in 5 years Sources: * Xalkori consensus from Thomson Cortellis (7 analysts) ** Zykadia consensus from Thomson Cortellis (4 analysts) *** Alecensa consensus from Thomson Cortellis (3 analysts) Global ALK Inhibitor Consens

Slide 15: Research & Development Key Investments
01.14.2015 J.P. Morgan Healthcare Conference Research & Development Key Investments J.P.

Slide 16: Our R&D strategy: focused on six investments
01.14.2015 Morgan Healthcare Conference Iclusig – doseranging trial in 3rd line CML Iclusig – randomized trial vs. nilotinib in 2nd line CML Iclusig – early-switch trial in 2nd line CML (SPIRIT3) Brigatinib – ALTA trial in refractory ALK+ NSCLC Brigatinib – randomized trial vs. crizotinib in 1st lin

Slide 17: Iclusig: dose-ranging 3rd line CML trial
01.14.2015 J.P. Morgan Healthcare Conference Iclusig: dose-ranging 3rd line CML trial Trial to open by mid-2015 Adult CP-CML patients resistant to ≥ 2 TKIs, N=450 Primary endpoint: MCyR by 12 months Minimum follow-up of 2 years 1:1:1 Randomization Dose reduction to 15 mg upon achievement of MCyR Pon

Slide 18: Iclusig: randomized phase trial in 2nd line CML
01.14.2015 J.P. Morgan Healthcare Conference Iclusig: randomized phase 3 trial in 2nd line CML Global trial evaluating two doses of ponatinib vs. nilotinib; N=~500 Key Features CML patients resistant to imatinib Population Primary endpoint of MMR by 12 months Efficacy Focus on arterial thrombotic ev

Slide 19: Iclusig: early-switch trial in 2nd line CML (SPIRIT3)
01.14.2015 J.P. Morgan Healthcare Conference Iclusig: early-switch trial in 2nd line CML (SPIRIT3) EMR = early molecular response (MR 10) Trial to open 1H 2015 Patients failing to reach EMR at 3 months switch to ponatinib Reduce dose in patients in MMR for ≥ 2 years; stop treatment if MMR maintained

Slide 20: Brigatinib: pivotal ALTA trial in refractory ALK+ NSCLC
01.14.2015 J.P. Morgan Healthcare Conference Brigatinib: pivotal ALTA trial in refractory LK+ NSCLC Primary endpoint = ORR Non-comparative trial Full patient enrollment expected in Q3 2015 Brigatinib 90 mg All Patients Global Trial N= 220 patients Includes patients with brain metastases Randomized 1

Slide 21: Key R&D milestones: next 3 years
01.14.2015 J.P. Morgan Healthcare Conference 2015 2016 2017 Iclusig • Start of 3 CML trials • Data presented from ISTs • Early data from dose-ranging trial Data presented from ISTs Approval in Japan Full patient enrollment in 2nd line trial Additional data from dose-ranging trial brigatinib Full pat

Slide 22: Achieving Profitability in 2018
01.14.2015 J.P. Morgan Healthcare Conference Marcele Wilson Chronic myeloid leukemia ARIAD clinical trial patient Achieving Profitability in 2018

Slide 23: Estimated FY 2014 financials
01.14.2015 J.P. Morgan 01.14.2015 Healthcare Conference Revenue – product and license $100 Selling, general and administrative expenses $140 Research and development expenses $120 Cash and cash equivalents as of 12/31/14 $350 2014 Key financial results *All amounts presented are unaudited estimates;

Slide 24: Path to sustained profitability
01.14.2015 J.P. Morgan Healthcare Conference Path to sustained profitability 2015 2016 2017 2018 Revenue growth and partnerships drive increased cash flow Iclusig revenue growth in U.S. and Europe from current label Iclusig revenue from Japan and new geographies Brigatinib revenue and partnership pa

Slide 25: ARIAD 2015: key catalysts
01.14.2015 J.P. Morgan Healthcare Conference ARIAD 2015: key catalysts Accelerate Iclusig sales in U.S. and Europe Initiate key Iclusig trials Dose-ranging trial Randomized 2nd line trial vs. nilotinib Early- switch 2nd line trial (SPIRIT3) Secure broad partnership for brigatinib Present early data

Slide 26: ARIAD
ARIAD®
Source: SEC EDGAR · 8-K filed Jan 14, 2015
